Zimmer Biomet Holdings ((ZBH)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Study Overview: Zimmer Biomet Holdings is conducting a post-market clinical follow-up study titled ‘Post-market Clinical Follow-up Study to Collect Safety, Performance and Clinical Benefits of the ComposiTCP™ Suture Anchors Double Loaded With BroadBand Tape, Sliding.’ The study aims to collect data on the safety, performance, and clinical benefits of these suture anchors when used in rotator cuff repair, with a focus on healing, functional outcomes, and safety.
Intervention/Treatment: The intervention being tested is the ComposiTCP Suture Anchors Double Loaded with BroadBand Tape, Sliding. These are used in rotator cuff repairs to enhance soft tissue to bone healing in the shoulder.
Study Design: This is an observational study with a cohort model, involving a consecutive series of patients. It is non-randomized and non-controlled, focusing on real-world data collection without specific interventions administered during the study.
Study Timeline: The study began on July 15, 2025, with the latest update submitted on August 6, 2025. These dates are crucial as they mark the study’s initiation and the most recent information available, indicating the study’s active recruitment status.
Market Implications: This study could potentially impact Zimmer Biomet’s stock performance positively by demonstrating the efficacy and safety of their product, which may enhance investor confidence. In the competitive medical device industry, successful outcomes could position Zimmer Biomet favorably against competitors, potentially influencing market dynamics.
The study is ongoing, with further details available on the ClinicalTrials portal.